View More View Less
  • 1 Pangea Biomedics, Mexico
  • 2 International Center for Ethnobotanical Education, Research & Services, Spain
  • 3 University of São Paulo, Brazil
  • 4 National Institute of Science and Technology – Translational Medicine, Brazil
  • 5 Universidad Autónoma de Madrid, Spain
Restricted access

Background and aims

Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, the majority of reports described cases of heroin-dependent individuals, with and without concomitant use of methadone, using high doses of ibogaine. Therefore, it is not clear if ibogaine at low doses could be used therapeutically in people on methadone maintenance treatments (MMT).

Methods

Case report of a female on MMT for 17 years who performed a self-treatment with several low and cumulative doses of ibogaine over a 6-week period.

Results

The patient successfully eliminated her withdrawals from methadone with ibogaine. Each administration of ibogaine attenuated the withdrawal symptoms for several hours, and reduced the tolerance to methadone until all signs of withdrawal symptoms disappeared at the end of the treatment. No serious adverse effects were observed, and at no point did the QTc measures reach clinically significant scores. Twelve months after the treatment, she was no longer on MMT.

Conclusions

To our knowledge, this is the first case report describing an ibogaine treatment using low and cumulative doses in a person on MMT. Although preliminary, this case suggests that low and cumulative doses of ibogaine may reduce withdrawal symptoms in patients undergoing MMT.

  • Alper, K. R. (2001). Ibogaine: A review. The Alkaloids: Chemistry and Biology, 56, 138. doi:10.1016/S0099-9598(01)56005-8

  • Argoff, C. E., & Silvershein, D. I. (2009). A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: Tailoring therapy to meet patient needs. Mayo Clinic Proceedings, 84(7), 602612. doi:10.1016/S0025-6196(11)60749-0

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Belgers, M., Leenaars, M., Homberg, J. R., Ritskes-Hoitinga, M., Schellekens, A. F., & Hooijmans, C. R. (2016). Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Translational Psychiatry, 6(5), e826. doi:10.1038/tp.2016.71

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Bradley, B., Gossop, M., Phillips, G., & Legarda, I. (1987). The development of an opiate withdrawal score (OWS). British Journal of Addiction, 82(10), 11391142. doi:10.1111/j.1360-0443.1987.tb03294.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Brown, T. K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6(1), 316. doi:10.2174/15672050113109990001

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Centers for Disease Control and Prevention. (2016). Injury Prevention & Control: Opioid Overdose. Understanding the Epidemic. Retrieved from http://www.cdc.gov/drugoverdose/epidemic/index.html (accessed on July 14, 2016).

    • Search Google Scholar
    • Export Citation
  • European Monitoring Centre for Drugs and Drug Addiction [EMCDDA]. (2016). European Drug Report. Trends and Developments. 2016. Retrieved from http://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001ENN.pdf (accessed on July 14, 2016)

    • Search Google Scholar
    • Export Citation
  • Fujita-Hamabe, W., Nagae, R., Nawa, A., Harada, S., Nakamoto, K., & Tokuyama, S. (2010). Involvement of kappa opioid receptors in the formalin-induced inhibition of analgesic tolerance to morphine via suppression of conventional protein kinase C activation. Journal of Pharmacy and Pharmacology, 62(8), 9951002. doi:10.1111/j.2042-7158.2010.01117.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Gray, A., Hung, N., Hung, C. T., Harland, S., Devane, J., Howes, J., Weis, H., & Friedhoff, L. (2016). Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. Journal of Clinical Pharmacology, 56(8), 960965. doi:10.1002/jcph.704

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., Hung, C. T., Harland, S., Devane, J., Crockett, R. S., Howes, J., Darpo, B., Zhou, M., Weis, H., & Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460468. doi:10.1002/cpdd.25410.1002/cpdd.254

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Gossop, M. (1990). The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors, 15(5), 487490. doi:10.1016/0306-4603(90)90036-W

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Gutwinski, S., Bald, L. K., Gallinat, J., Heinz, A., & Bermpohl, F. (2014). Why do patients stay in opioid maintenance treatment? Substance Use and Misuse, 49(6), 694699. doi:10.3109/10826084.2013.863344

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Ibogaine Legal Status. (2016). Retrieved from https://www.ibogainealliance.org/ibogaine/law/ (accessed on July 27, 2016).

  • Lingjaerde, O., Ahlfors, U. G., Bech, P., Denckes, S. J., & Elgen, K. (1987). The UKU side effects rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neurologic-treated patients. Acta Psychiatrica Scandinavica, 76, 1100. doi:10.1111/j.1600-0447.1987.tb10566.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Litjens, R. P., & Brunt, T. M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297302. doi:10.3109/15563650.2016.1138226

  • Maciulaitis, R., Kontrimaviciute, V., Bressolle, F. M., & Briedis, V. (2008). Ibogaine, an anti-addictive drug: Pharmacology and time to go further in development. A narrative review. Human and Experimental Toxicology, 27(3), 181194. doi:10.1177/0960327107087802

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Maillet, E. L., Milon, N., Heghinian, M. D., Fishback, J., Schürer, S. C., Garamszegi, N., & Mash, D. C. (2015). Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology, 99, 675688. doi:10.1016/j.neuropharm.2015.08.032

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Mash, D. C., Ameer, B., Prou, D., Howes, J. F., & Maillet, E. L. (2016). Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. Journal of Psychopharmacology, 30(7), 688697. doi:10.1177/0269881116641331

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences, 844, 274292. doi:10.1111/j.1749-6632.1998.tb08242.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., Singleton, E. G., & Mayor, M. (2000). Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 914(1), 394401. doi:10.1111/j.1749-6632.2000.tb05213.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992). The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment, 9(3), 199213. doi:10.1016/0740-5472(92)90062-S

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Meisner, J. A., Wilcox, S. R., & Richards, J. B. (2016). Ibogaine-associated cardiac arrest and death: Case report and review of the literature. Therapeutic Advances in Psychopharmacology, 6(2), 9598. doi:10.1177/2045125315626073

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10(3), 799812. doi:10.2466/pr0.1962.10.3.799

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Pedrero-Pérez, E. J., & MethaQoL, G. (2016). Methadone dosage and its relationship to quality of life, satisfaction, psychopathology, cognitive performance and additional consumption of non-prescribed drugs. Adicciones, 29, 3754. doi:10.20882/adicciones.831

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Scavone, J. L., Sterling, R. C., Weinstein, S. P., & Van Bockstaele, E. J. (2013). Impact of cannabis use during stabilization on methadone maintenance treatment. American Journal on Addictions, 22(4), 344351. doi:10.1111/j.1521-0391.2013.12044.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Schep, L. J., Slaughter, R. J., Galea, S., & Newcombe, D. (2016). Ibogaine for treating drug dependence. What is a safe dose? Drug and Alcohol Dependence, 166, 15. doi:10.1016/j.drugalcdep.2016.07.005

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Sheehan, D. V., Lecrubier, Y., Harnett-Sheehan, K., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., & Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview. Journal of Clinical Psychiatry, 59, 2223. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9881538

    • Search Google Scholar
    • Export Citation
  • Spangler, T. (2016). Drug abuse bill passes U.S. House, sent to Senate. Detroit Free Press (July 8). Retrieved from http://www.freep.com/story/news/politics/2016/07/08/drug-abuse-bill-passes-us-house-sent-senate/86863484/ (accessed on July 14, 2016)

    • Export Citation
  • Substance Abuse and Mental Health Services Administration [SAMHSA]. (2016). Opioids. Retrieved from http://www.samhsa.gov/atod/opioids (accessed on July 14, 2016)

    • Export Citation
  • United States Patent Office. (1957). Tabernanthine, ibogaine containing analgesic compositions. Patented December 24. US2817623 A. Retrieved from http://www.google.com/patents/US2817623?hl=es (accessed on July 14, 2016)

    • Export Citation
  • World Health Organization [WHO]. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Retrieved from http://apps.who.int/iris/bitstream/10665/43948/1/9789241547543_eng.pdf (accessed on July 14, 2016)

    • Export Citation

Language: English
Founded in 2016
Publication: Online Only
Publication Programme: 2020: Vol. 4.

 

Editor-in-Chief:

Attila Szabo - University of Oslo

E-mail address: attilasci@gmail.com

Associate Editors:

  • Alan K. Davis - The Ohio State University & Johns Hopkins University, USA
  • Zsolt Demetrovics - Eötvös Lóránd University, Budapest, Hungary
  • Ede Frecska, founding Editor-in-Chief - University of Debrecen, Debrecen, Hungary
  • David Luke - University of Greenwich, London, UK
  • Dennis J. McKenna- Heffter Research Institute, St. Paul, USA
  • Jeremy Narby - Swiss NGO Nouvelle Planète, Lausanne, Switzerland
  • Stephen Szára - Retired from National Institute on Drug Abuse, Bethesda, USA
  • Michael Winkelman - Retired from Arizona State University, Tempe, USA 

Book Reviews Editor:

Michael Winkelman - Retired from Arizona State University, Tempe, USA

Editorial Board

  • Gábor Andrássy - University of Debrecen, Debrecen, Hungary
  • Tiago Arruda-Sanchez - Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Paulo Barbosa - State University of Santa Cruz, Bahia, Brazil
  • Michael Bogenschutz - New York University School of Medicine, New York, NY, USA
  • Petra Bokor - University of Pécs, Pécs, Hungary
  • Jose Bouso - Autonomous University of Madrid, Madrid, Spain
  • Zoltán Brys - Multidisciplinary Soc. for the Research of Psychedelics, Budapest, Hungary
  • Susana Bustos - California Institute of Integral Studies San Francisco, USA
  • Robin Carhart-Harris - Imperial College, London, UK
  • Valerie Curran - University College London, London, UK
  • Alicia Danforth - Harbor-UCLA Medical Center, Los Angeles, USA
  • Rick Doblin - Boston, USA
  • Rafael G. dos Santos - University of Sao Paulo, Sao Paulo, Brazil
  • Genis Ona Esteve - Rovira i Virgili University, Spain
  • Silvia Fernandez-Campos
  • Andrew Gallimore - University of Cambridge, Cambridge, UK
  • Neal Goldsmith - private practice, New York, NY, USA
  • Charles Grob - Harbor-UCLA Medical Center, Los Angeles, CA, USA
  • Stanislav Grof - California Institute of Integral Studies, San Francisco, CA, USA
  • Karen Grue - private practice, Copenhagen, Denmark
  • Kathleen Harrison
  • Jiri Horacek - Charles University, Prague, Czech Republic
  • Lajos Horváth - University of Debrecen, Debrecen, Hungary
  • Robert Jesse - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Matthew Johnson - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Anita Kazai
  • István Kelemen - University of Debrecen, Debrecen, Hungary
  • Eli Kolp - Kolp Institute New, Port Richey, FL, USA
  • Stanley Krippner - Saybrook University, Oakland, CA, USA
  • Evgeny Krupitsky - St. Petersburg State Pavlov Medical University, St. Petersburg, Russia
  • Rafael Lancelotta - Innate Path, Lakewood, CO, USA
  • Anja Loizaga-Velder - National Autonomous University of Mexico, Mexico City, Mexico
  • David Lukoff
  • Luis Luna - Wasiwaska Research Center, Florianópolis, Brazil
  • Katherine MacClean - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Deborah Mash - University of Miami School of Medicine, Miami, USA
  • Friedericke Meckel - private practice, Zurich, Switzerland
  • Ralph Metzner - California Institute of Integral Studies, San Francisco, CA, USA
  • Dale Millard
  • Michael Mithoefer - private practice, Charleston, SC, USA
  • Levente Móró - University of Turku, Turku, Finland
  • David Nichols - Purdue University, West Lafayette, IN, USA
  • David Nutt - Imperial College, London, UK
  • Torsten Passie - Hannover Medical School, Hannover, Germany
  • Janis Phelps - California Institute of Integral Studies, San Francisco, CA, USA
  • József Rácz - Semmelweis University, Budapest, Hungary
  • Christian Rätsch - University of California, Los Angeles, Los Angeles, CA, USA
  • Jordi Riba - Sant Pau Institute of Biomedical Research, Barcelona, Spain
  • Sidarta Ribeiro - Federal University of Rio Grande do Norte, Natal, Brazil
  • William Richards - Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Stephen Ross - New York University, New York, NY, USA
  • Brian Rush - University of Toronto, Toronto, Canada
  • Eduardo Schenberg - Federal University of São Paulo, São Paulo, Brazil
  • Ben Sessa - Cardiff University School of Medicine, Cardiff, UK
  • Lowan H. Stewart - Santa Fe Ketamine Clinic, NM, USA (Medical Director)
  • Rebecca Stone - Emory University, Atlanta, GA, USA
  • Rick Strassman - University of New Mexico School of Medicine, Albuquerque, NM, USA
  • Attila Szabó - University of Oslo, Oslo, Norway
  • Csaba Szummer - Károli Gáspár University of the Reformed Church, Budapest, Hungary
  • Manuel Torres - Florida International University, Miami, FL, USA
  • Luís Fernando Tófoli - University of Campinas, Campinas, Brazil State
  • Malin Uthaug - Maastricht University, Maastricht, The Netherlands
  • Julian Vayne - Norwich, UK
  • Nikki Wyrd - Norwich, UK

Attila Szabo
University of Oslo

E-mail address: attilasci@gmail.com

The author instruction is available in PDF.
Please, download the file from HERE

Book Review Guidelines are available from HERE

 

 

MANUSCRIPT SUBMISSION